A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent gliomaPARKER, Ricardo J; FRUEHAUF, John P; MEHTA, Rita et al.Journal of neuro-oncology. 2004, Vol 66, Num 3, pp 365-375, issn 0167-594X, 11 p.Article

Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion)GOTO, Shigenori; SHIROTANI, Noriko; HATAKEYAMA, Masahiko et al.Anticancer research. 2002, Vol 22, Num 4, pp 2461-2464, issn 0250-7005, 4 p.Article

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapyCOUDERT, B; CIULEANU, T; PARK, K et al.Annals of oncology. 2012, Vol 23, Num 2, pp 388-394, issn 0923-7534, 7 p.Article

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trialCOLOMBO, N; MCMEEKIN, D. S; EINSTEIN, M. H et al.British journal of cancer. 2013, Vol 108, Num 5, pp 1021-1026, issn 0007-0920, 6 p.Article

A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myelomaAGRAWAL, Neeraj R; BUKOWSKI, Ronald M; RYBICKI, Lisa A et al.Cancer. 2003, Vol 98, Num 1, pp 94-99, issn 0008-543X, 6 p.Article

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable diseaseROSINOL, Laura; GARCIA-SANZ, Ramón; CARLOS GARCIA-RUIZ, Juan et al.Haematologica (Roma). 2012, Vol 97, Num 4, pp 616-621, issn 0390-6078, 6 p.Article

Immunotherapy in Patients with Less than Complete Response to ChemotherapyRECCHIA, Francesco; CANDELORO, Giampiero; NECOZIONE, Stefano et al.Anticancer research. 2009, Vol 29, Num 2, pp 567-572, issn 0250-7005, 6 p.Article

Parametric estimation procedures for screening programmes : Stable and nonstable disease models for multimodality case findingYU SHEN; ZELEN, M.Biometrika. 1999, Vol 86, Num 3, pp 503-515, issn 0006-3444Article

WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trialMIYATAKE, Takashi; UEDA, Yutaka; NAKATSUKA, Shin-Ichi et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 3, pp 457-463, issn 0171-5216, 7 p.Article

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient casesDI GIACOMO, Anna Maria; DANIELLI, Riccardo; MAIO, Michele et al.Cancer immunology and immunotherapy. 2009, Vol 58, Num 8, pp 1297-1306, issn 0340-7004, 10 p.Article

Stable disease in advanced colorectal cancer : Therapeutic implicationsPASETTO, Lara Maria; D'ANDREA, Mario Rosario; JIRILLO, Antonio et al.Anticancer research. 2006, Vol 26, Num 1B, pp 511-522, issn 0250-7005, 12 p.Article

Tumour growth rates and RECIST criteria in early drug developmentGOMEZ-ROCA, Carlos; KOSCIELNY, Serge; RIBRAG, Vincent et al.European journal of cancer (1990). 2011, Vol 47, Num 17, pp 2512-2516, issn 0959-8049, 5 p.Article